elosulfase alfa

This medicine is authorised for use in the European Union.


This is a summary of the European public assessment report (EPAR) for Vimizim. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Vimizim.

For practical information about using Vimizim, patients should read the package leaflet or contact their doctor or pharmacist.

This EPAR was last updated on 08/11/2018

Authorisation details

Product details
Agency product number
Active substance
recombinant human n-acetylgalactosamine-6-sulfatase (rhgalns)
International non-proprietary name (INN) or common name
elosulfase alfa
Therapeutic area (MeSH)
Mucopolysaccharidosis IV
Anatomical therapeutic chemical (ATC) code
Additional monitoring

This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines. For more information, see Medicines under additional monitoring.


This medicine was designated an orphan medicine. This means that it was developed for use against a rare, life-threatening or chronically debilitating condition or, for economic reasons, it would be unlikely to have been developed without incentives. For more information, see Orphan designation

Publication details
Marketing-authorisation holder
BioMarin International Limited
Date of issue of marketing authorisation valid throughout the European Union
Contact address

Shanbally, Ringaskiddy
County Cork, P43 R298

Product information

28/09/2018 Vimizim - EMEA/H/C/002779 - T/0026


  • Annex I - Summary of product characteristics
  • Annex IIA - Manufacturing-authorisation holder responsible for batch release
  • Annex IIB - Conditions of the marketing authorisation
  • Annex IIIA - Labelling
  • Annex IIIB - Package leaflet

Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.

Pharmacotherapeutic group

Other alimentary tract and metabolism products

Therapeutic indication

Vimizim is indicated for the treatment of mucopolysaccharidosis, type IVA (Morquio A Syndrome, MPS IVA) in patients of all ages.

Assessment history

How useful was this page?

Add your rating
1 rating